Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Expansion of Modus study ‘great news for Ergomed Plc’

Wednesday, November 16, 2016 9:30
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics.

The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat people suffering from Sickle Cell Disease.

Ergomed Chief business officer Andrew Mackie tells Proactive: ”It’s great news for us. The Independent Data Safety Monitoring Board have had a look at the first 25 patients included in the study and they’ve concluded that it’s safe to continue.”

”Also, because of the safety profile seen so far they’ve actually allowed us to open up the recruitment to young patients – this will enable us to increase the pace of recruitment in the study … and ultimately when it gets to market it will be able to serve a wider population”.

Top line are results now expected in the first half of 2018 rather than in the first half of next year.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.